Book a Call
MDside
Book a Call

Retatrutide in phase 3, and the gray market that got there first

  • MDside
  • October 9, 2026

Key points

  • In the phase 3 TRIUMPH-1 trial (2,339 adults, 80 weeks), the 12 mg dose was associated with a 25.0% body-weight reduction vs 3.9% with placebo [2].
  • As of this writing we found no regulatory approval of retatrutide [2][4].
  • FDA has sent warning letters to sellers of retatrutide labeled “for research” [4][5][6], and Eli Lilly sued six companies in 2026 [7].
  • The claim that “Panama has banned retatrutide” circulates in foreign media, but we found no MINSA rule behind it [9].

US status (October 2026): Retatrutide is not FDA-approved for any use, and FDA states it cannot be used in compounding under federal law. MDside providers do not prescribe it.

Retatrutide has some of the strongest obesity data published. It also reached patients through an illegal channel years before approval. Your patients have seen both stories, and you need an answer for each.

Retatrutide is a triple agonist with a viral number

Retatrutide is a triple agonist: it acts on the GLP-1, GIP and glucagon receptors at once [11]. In phase 2 (338 adults with obesity), the 12 mg dose was associated with a 24.2% body-weight reduction at 48 weeks vs 2.1% with placebo [1]. The number spread on social media long before any approval.

Phase 3 confirmed the effect and added safety signals

TRIUMPH-1 was published on September 29, 2026: 2,339 adults without diabetes, 80 weeks. Body weight fell 17.6%, 23.7% and 25.0% with 4, 9 and 12 mg, vs 3.9% with placebo. Knee-osteoarthritis pain and sleep apnea also improved [2]. Gastrointestinal effects were the most common [2].

TRIUMPH-2, in 1,152 adults with obesity and type 2 diabetes, associated the 12 mg dose with an 18.8% body-weight reduction at 80 weeks vs 5.1% with placebo (a 13.8-point difference). Diarrhea (27 to 34% vs 13%) and nausea (14 to 28% vs 8%) were more frequent than with placebo, as were hypotension (1 to 6% vs under 1%) and dysesthesia (abnormal skin sensations, 4 to 7% vs 1%) [3]. For the full trial detail and patient talking points, see retatrutide trial results: what to tell patients.

  • 25.0%: body-weight reduction at 80 weeks on 12 mg in TRIUMPH-1 [2]
  • 2,339: adults in TRIUMPH-1 [2]
  • 0: regulatory approvals found as of October 2026 [2][4]

The gray market got there first

While the trials were still running, retatrutide was already sold online as a “research peptide.” In December 2024 FDA sent a warning letter to Summit Research Peptides for selling semaglutide, tirzepatide, retatrutide, cagrilintide and mazdutide, concluding that evidence from its websites established the products were “drugs for human use” [5]. In August 2026 it sent another to Royal Peptides, whose labels said “for research use only” and “not for human or animal consumption” [6].

FDA keeps a page on unapproved GLP-1s warning against semaglutide, tirzepatide, retatrutide and other products sold “for research” [4]. In August 2026 Eli Lilly sued six companies. According to Healio, Lilly says the sellers “falsely claim their drugs are for ‘research-use only’ when they are intended for human use” [7]. The label did not protect these sellers. See what “research use only” means.

Nobody has published what is in retatrutide vials

We found no published analyses of retatrutide bought online. There are analyses for semaglutide. A study that made test purchases from six illegal online pharmacies found, in the vials received, purity of 7.7% to 14.4% vs the 99% claimed, and endotoxin in every sample. The three pens ordered never arrived [10].

What happened in Latin America, and why US clinics should care

In Colombia, INVIMA included retatrutide in its alert 184-2026 on fraudulent peptides offered on Instagram and a website [8]. An Argentine outlet reported in August 2026 that “countries such as Brazil, Paraguay, Colombia and Panama have already banned the sale of Retatrutide” [9].

Fact-check. We found no MINSA resolution, DNFD notice or Official Gazette publication that specifically bans retatrutide in Panama. What can be verified is narrower: a drug not approved in any country cannot hold a Panamanian sanitary registration. We treat the “ban” as a rumor until we see the document [9]. The lesson for US clinics: patients and vendors repeat regulatory claims that have no document behind them. Ask for the document.

The supporters’ case is about the molecule

According to the published trials, retatrutide is one of the most effective obesity drugs studied: a 25.0% reduction at 80 weeks in phase 3 [2]. The data support the molecule. The controversy is about the channel: unapproved products sold before the manufacturer finishes development [5][6][7].

What this means for your clinic

Until approval, there is no lawful retatrutide for your patients. Explain the data honestly, explain why the online product is a different thing, and offer what is approved today through a structured weight management program. Our retatrutide status note is a good page to send a patient who asks.

References

  1. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315. Link
  2. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. Published online 29 September 2026. doi:10.1056/NEJMoa2604169. PMID 42814954. Link
  3. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PMID 42810372. Link
  4. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Updated 1 October 2026. Link
  5. U.S. Food and Drug Administration. Warning Letter: Summit Research Peptides (MARCS-CMS 695607). 10 December 2024. Link
  6. U.S. Food and Drug Administration. Warning Letter: Royal Peptides LLC (MARCS-CMS 734884). 24 August 2026. Link
  7. Monostra M. Eli Lilly files lawsuits against six companies for allegedly selling retatrutide. Healio. 14 August 2026. Link
  8. INVIMA (Colombia). Alerta Sanitaria No. 184-2026: Péptidos fraudulentos. 24 de junio de 2026. Link
  9. Contexto Tucumán (Argentina). ANMAT alertó por la venta ilegal de un fármaco experimental para adelgazar que fue expuesto por una conocida influencer. 22 de agosto de 2026. Link
  10. Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res. 2024;26:e65440. PMID 39509151. Link
  11. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID 35985340. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.

Share this article with a friend

Medical direction. Victor D. Cruz, MD, Systems Medical Director, licensed in Florida (ME117105) and New York, directs structure, corporate practice of medicine, delegation and good faith exams. This states who carries clinical responsibility for this subject area. It is not a page-level review: pages that have been reviewed name the reviewer and show the date. How this site is written and checked.